TORONTO, Ontario, Oct. 23, 2017 /Weed Wire/ — Khiron Life Sciences Corp. (“Khiron” or the “Company”) reports that further to its press release dated September 26, 2017, the Company’s wholly owned subsidiary, Khiron Colombia SAS, has been granted all the licences required for the cultivation, production, domestic distribution and international export of both low and high tetrahydrocannabinol (“THC”) medical cannabis in the country of Colombia. Khiron is the first company to be fully licenced in Colombia as set forth in the public resolution registries of the Ministry of Justice and Ministry of Health, and is now in position to commence cultivation of medicinal grade cannabis on its 7 hectares of approved lands with an additional 13 hectares under option. The license permit for high THC cultivation is Resolution 841 of 2017 issued by The Ministry of Justice.
Mr. Alvaro Torres, President and CEO of the Company, comments: “Khiron has now received all three requisite licences in Colombia, and we are positioned to continue the expansion of our business plan throughout Latin America. I would again like to thank the government of Colombia for their confidence in our team.”
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is a Canadian integrated medical cannabis company with its core operations in Colombia. Khiron combines leading international scientific expertise, agricultural advantages, and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America.
On behalf of the Board of Directors
Chief Executive Officer
Direct: +57 (320) 4950326
Chief Financial Officer
Direct: +1 (705) 527 3564
Further information on the Company can be accessed through the link below: